ClinicalTrials.gg
RecruitingNCT07711002EvoPAR-PR05Updated Oct 15, 2026

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

A Phase 3 interventional study of Saruparib and Placebo in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), sponsored by AstraZeneca. Recruiting at 210 sites in 21 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 15, 2026Now RecruitingFirst sites in 20 new countries+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,330
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Planned enrollment
6th of 60
1,330 · median 110
Started
2026
with 6 others
Phase 3
17 of 91
3 open now
Primary completion
2031-05
later than 26 of 28 live
Registered
91st of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 6th largest by planned enrollment of the 60 interventional ones that give a count, is one of 7 that started in 2026, is one of 17 in phase 3, reaches primary completion later than 26 of the 28 other live ones, and was the 91st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.

03

Conditions studied

  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Browse trials for

Keywords

  • Saruparib
  • HRRm
  • non-HRRm
  • mHSPC
  • Prostate Cancer
  • AZD5305
  • PSA>0.2ng/ml
  • Androgen pathway modulation sensitive (APMS)
  • Castration sensitive
  • Metastatic prostate cancer
  • Hormone sensitive prostate cancer
  • PARPi
  • Docetaxel
  • PSMA-directed 177Lutetium
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 at the time of signing the .
  • documented diagnosis of prostate adenocarcinoma that is de novo or recurrent and hormone-sensitive.
  • disease confirmed prior to initiation of previous treatment with docetaxel or Lu-PSMA-containing regimens for mHSPC.
  • Previous treatment with docetaxel (IV, Q3w)- or Lu-PSMA (IV, Q6w) with last dose within past 6 months.
  • Participants must have the following:

    • Must be receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy.
    • Had no evidence of disease progression
    • Had all toxicities related to docetaxel- or Lu-PSMA-containing treatment (except for alopecia and peripheral neuropathy) resolved to Grade 1 or lower.
  • PSA ≥ 0.2 ng/mL within 14 days prior to randomization.
  • Serum testosterone \< 1.7 nmol/L or 50 ng/dL.
  • Palliative radiotherapy for symptoms management will be permitted and is to be completed at least 4 weeks prior to randomization for wide field radiation therapy and at least 2 weeks prior to randomization for limited field radiation therapy.
  • Provision of a FFPE tumor tissue sample and a blood sample (for ctDNA).
  • Confirmed HRRm, HRD and PTEN status.
  • Adequate organ and bone marrow function.
  • Minimum of 6 months.
  • Male, assigned at birth, inclusive of all gender identities.
  • use by participants or participant partners should be consistent with local regulations.
  • Capable of giving signed informed consent.
  • - -

Exclusion criteria

Exclusion Criteria:

  • to saruparib, ARPI or any of these products or any or restriction based on the local label.
  • Any history of persisting (> 2 weeks) severe cytopenia due to any cause (eg, ANC\< 0.5 × 10\^9/L or \< 50 × 10\^9/L)
  • Any known predisposition to bleeding (eg, active peptic ulceration, recent [within6 months] hemorrhagic stroke, proliferative diabetic retinopathy.
  • Spinal cord compression or unless asymptomatic and stable.
  • History of MDS/AML or with features suggestive of MDS/AML
  • History of another primary , with some exceptions.
  • Any chronic gastrointestinal diseases or conditions including inability to swallow the formulated product that would preclude adequate absorption of any study drug.
  • History of seizure or predispose to seizure, including any history of loss of consciousness or within 12 months of enrolment.
  • Serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
  • Major surgical procedure or significant traumatic injury within 4 weeks of the first dose or an anticipated need for major surgery during the study.
  • Switched ARPI agent in previous treatment for mHSPC due to disease progression. Note: if the ARPI agent was switched due to any reason other than disease progression and switch was prior to ICF signature, participants will be eligible.
  • Any prior treatment with a PARPi or platinum chemotherapy.
  • - -
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,330 participants (estimated)

Study arms

  • Experimental
    Saruparib (AZD5305) + Physician's Choice ARPI - enzalutamide, darolutamide, or abiraterone

    Saruparib 60 mg + ARPI (enzalutamide, darolutamide, or abiraterone) : Participants will receive saruparib 60 mg orally once daily in combination with physician's choice of ARPI in cycles of 28 days

    Drug: Saruparib · Drug: Enzalutamide · Drug: Darolutamide · Drug: Abiraterone

  • Placebo comparator
    Placebo + Physician's Choice ARPI - enzalutamide, darolutamide, or abiraterone

    Placebo + ARPI (enzalutamide, darolutamide, or abiraterone): Participants will receive placebo orally once daily in combination with physician's choice of ARPI in cycles of 28 days

    Other: Placebo · Drug: Enzalutamide · Drug: Darolutamide · Drug: Abiraterone

Interventions

  • Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone)

  • OtherPlacebo

    Arm 2: Placebo + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone)

  • Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone) Arm 2: Placebo + Physician's Choice ARPI

  • Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone) Arm 2: Placebo + Physician's Choice ARPI

  • Arm 1: Saruparib (AZD5305) + Physician's Choice ARPI (enzalutamide, darolutamide, or abiraterone) Arm 2: Placebo + Physician's Choice ARPI

06

What researchers measure

Primary outcomes

  1. Radiographic progression-free survival (rPFS)

    Radiographic PFS (rPFS) is the primary endpoint of this study, defined as the time from randomization to radiographic progression, as assessed by the investigator per RECIST 1.1 (soft tissue) and/or PCWG3 criteria (bone), or death due to any cause.

    Time frame: Up to approximately 56 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization until death due to any cause.

    Time frame: Up to approximately 80 months

  2. Radiographic progression-free survival (rPFS)

    Radiographic PFS (rPFS) is the primary endpoint of this study, defined as the time from randomization to radiographic progression, as assessed by the investigator per RECIST 1.1 (soft tissue) and/or PCWG3 criteria (bone), or death due to any cause.

    Time frame: Up to approximately 56 months

  3. Time to Second Progression or Death (PFS2)

    PFS2 is defined as the time from randomization to the earliest progression (defined as radiographic progression, clinical progression, or PSA progression) after initiation of first subsequent treatment following the initial investigator-assessed progression or death (ie, date of PFS2 event or censoring - date of randomization + 1).

    Time frame: Up to approximately 56 months

  4. Time to First Subsequent Therapy or Death (TFST)

    TFST is defined as the time from randomization to the start date of the first subsequent anticancer therapy after discontinuation of randomized treatment, or death due to any cause (ie, date of first subsequent cancer therapy or death - date of randomization + 1).

    Time frame: Up to approximately 56 months

  5. Symptomatic Skeletal Event-free Survival (SSE-FS)

    SSE-FS is defined as the time from the date of randomization to the earliest of the following: * Use of radiation therapy to prevent or relieve skeletal symptoms. * Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). Radiographic documentation is required. A pathological fracture, as determined by investigator, is defined as associated with low or no trauma and deemed to have occurred at a site of bone metastasis. * Occurrence of spinal cord compression. Radiographic documentation is required. * Orthopedic surgical intervention for bone metastasis. * Death due to any cause.

    Time frame: Up to approximately 56 months

  6. Time to Castration Resistance (TTCR)

    TTCR is defined as the time from randomization to the first castration-resistant event (radiographic disease progression, PSA progression per PCWG3, or SSE, whichever occurs first, with castrate levels of testosterone below 50 ng/dL).

    Time frame: Up to approximately 56 months

  7. Time to PSA progression

    Time to PSA progression, defined as the time from randomization to PSA progression per PCWG3 criteria.

    Time frame: Up to approximately 56 months

  8. Time to deterioration in physical function (TTDPF)

    TTDPF is defined as the time from randomization to deterioration in PROMIS SF-PF scores.

    Time frame: Up to approximately 56 months

  9. Time to pain progression (TTPP)

    TTPP is defined as the time from randomization to clinically meaningful pain progression based on a 2-point increase from baseline in the BPI-SF Item 3 'worst pain in 24 hours' score and/or initiation of/increase in opioid analgesic use.

    Time frame: Up to approximately 56 months

  10. Brief Pain Inventory - Short Form (BPI-SF)

    Change from baseline in BPI-SF worst pain score, pain severity and interference domain scores.

    Time frame: Up to approximately 56 months

  11. Time to deterioration in urinary symptoms (TTDUS)

    TTDUS is defined as the time from randomization to deterioration in the EORTC QLQ-PR25(US) subscale scores.

    Time frame: Up to approximately 56 months

  12. Plasma concentrations of AZD5305

    To assess PK of AZD5305 in plasma

    Time frame: Day 1 of Cycle 1, Cycle 2 and Cycle 3 (each cycle is of 28 days)

07

Study locations

6 of 210 sites recruiting
  • Research Site
    Hot Springs, Arkansas 71913, United States
    Not yet recruiting
  • Research Site
    Springdale, Arkansas 72762, United States
    Recruiting
  • Research Site
    Beverly Hills, California 90211, United States
    Not yet recruiting
  • Research Site
    Los Alamitos, California 90720, United States
    Not yet recruiting
  • Research Site
    Los Angeles, California 90089, United States
    Not yet recruiting
  • Research Site
    San Diego, California 92123, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Margate, Florida 33063, United States
    Recruiting
  • Research Site
    Miami, Florida 33165, United States
    Recruiting
  • Research Site
    Orlando, Florida 32806, United States
    Not yet recruiting
  • Research Site
    Honolulu, Hawaii 96813, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60637, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60657, United States
    Not yet recruiting
  • Research Site
    Elk Grove Village, Illinois 60007, United States
    Not yet recruiting
  • Research Site
    Hinsdale, Illinois 60521, United States
    Not yet recruiting
  • Research Site
    Ames, Iowa 50010, United States
    Not yet recruiting
  • Research Site
    Baltimore, Maryland 21201, United States
    Not yet recruiting
  • Research Site
    Baltimore, Maryland 21229, United States
    Not yet recruiting
  • Research Site
    Towson, Maryland 21204, United States
    Not yet recruiting
  • Research Site
    Detroit, Michigan 48202, United States
    Not yet recruiting
  • Research Site
    Grand Rapids, Michigan 49503, United States
    Not yet recruiting
  • Research Site
    Marshall, Minnesota 56258, United States
    Not yet recruiting
  • Research Site
    Camden, New Jersey 08103, United States
    Not yet recruiting
  • Research Site
    Albuquerque, New Mexico 87109, United States
    Not yet recruiting
  • Research Site
    Shirley, New York 11967, United States
    Not yet recruiting
  • Research Site
    Canton, Ohio 44718, United States
    Not yet recruiting
  • Research Site
    Cincinnati, Ohio 45267, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97213, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97227, United States
    Not yet recruiting
  • Research Site
    Greenville, South Carolina 29607, United States
    Not yet recruiting
  • Research Site
    Aberdeen, South Dakota 57401, United States
    Not yet recruiting
  • Research Site
    Mitchell, South Dakota 57301, United States
    Not yet recruiting
  • Research Site
    Pierre, South Dakota 57501, United States
    Not yet recruiting
  • Research Site
    Sioux Falls, South Dakota 57105, United States
    Not yet recruiting
  • Research Site
    Yankton, South Dakota 57078, United States
    Not yet recruiting
  • Research Site
    Nashville, Tennessee 37203, United States
    Not yet recruiting
  • Research Site
    Austin, Texas 78745, United States
    Not yet recruiting
  • Research Site
    Dallas, Texas 75235, United States
    Not yet recruiting
  • Research Site
    Fort Worth, Texas 76104, United States
    Not yet recruiting
  • Research Site
    Longview, Texas 75605, United States
    Not yet recruiting
  • Research Site
    Wichita Falls, Texas 76310, United States
    Not yet recruiting
  • Research Site
    Salt Lake City, Utah 84112, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Spokane, Washington 99202, United States
    Not yet recruiting
  • Research Site
    Graz, 8036, Austria
    Not yet recruiting
  • Research Site
    Linz, 4020, Austria
    Not yet recruiting
  • Research Site
    Salzburg, 5020, Austria
    Not yet recruiting
  • Research Site
    Vienna, 1090, Austria
    Not yet recruiting
  • Research Site
    Barretos, 14784-400, Brazil
    Not yet recruiting
  • Research Site
    Brasília, 71681-603, Brazil
    Not yet recruiting
  • Research Site
    Natal, 59020-400, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, 90035-000, Brazil
    Not yet recruiting
  • Research Site
    São Caetano do Sul, 09541-270, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 01327-001, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 05652-900, Brazil
    Not yet recruiting
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
    Not yet recruiting
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
    Not yet recruiting
  • Research Site
    Abbotsford British Columbia, British Columbia V2S0C2, Canada
    Not yet recruiting
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
    Not yet recruiting
  • Research Site
    Kitchener, Ontario N2G 1G, Canada
    Not yet recruiting
  • Research Site
    North York, Ontario M2K 1E1, Canada
    Not yet recruiting
  • Research Site
    Ottawa, Ontario K1H 7W9, Canada
    Not yet recruiting
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
  • Research Site
    Windsor, Ontario N8W 1L9, Canada
    Not yet recruiting
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
    Not yet recruiting
  • Research Site
    Saint-Jérôme, Quebec J7Z 5T3, Canada
    Not yet recruiting
  • Research Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
    Not yet recruiting
  • Research Site
    Beijing, 100730, China
    Not yet recruiting
  • Research Site
    Changsha, 410013, China
    Not yet recruiting
  • Research Site
    Chengdu, 610031, China
    Not yet recruiting
  • Research Site
    Chengdu, 610078, China
    Not yet recruiting
  • Research Site
    Chongqing, 400030, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350005, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510289, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510515, China
    Not yet recruiting
  • Research Site
    Guiyang, 550044, China
    Not yet recruiting
  • Research Site
    Jiaxing, 314001, China
    Not yet recruiting
  • Research Site
    Jinan, 250021, China
    Not yet recruiting
  • Research Site
    Kunming, 650101, China
    Not yet recruiting
  • Research Site
    Kunming, 650118, China
    Not yet recruiting
  • Research Site
    Lanzhou, 730030, China
    Not yet recruiting
  • Research Site
    Nanchang, 330000, China
    Not yet recruiting
  • Research Site
    Nanjing, 210009, China
    Not yet recruiting
  • Research Site
    Nantong, 226361, China
    Not yet recruiting
  • Research Site
    Ningbo, 315020, China
    Not yet recruiting
  • Research Site
    Qingdao, 266035, China
    Not yet recruiting
  • Research Site
    Shandong, China
    Not yet recruiting
  • Research Site
    Shanghai, 200025, China
    Not yet recruiting
  • Research Site
    Shanghai, 200080, China
    Not yet recruiting
  • Research Site
    Wenzhou, 325000, China
    Not yet recruiting
  • Research Site
    Wuhan, 430030, China
    Not yet recruiting
  • Research Site
    Wuhan, 430048, China
    Not yet recruiting
  • Research Site
    Wuhan, 430079, China
    Not yet recruiting
  • Research Site
    Xi'an, 710061, China
    Not yet recruiting
  • Research Site
    Angers, 49100, France
    Not yet recruiting
  • Research Site
    Caen, 14076, France
    Not yet recruiting
  • Research Site
    Montpellier, 34298, France
    Not yet recruiting
  • Research Site
    Paris, 75014, France
    Not yet recruiting
  • Research Site
    Poitiers, 86021, France
    Not yet recruiting
  • Research Site
    Bergisch Gladbach, 51465, Germany
    Not yet recruiting

Showing the first 100 of 210 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2031, 56 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 56 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Oct 2026 → Sep 2026, primary completion Jun 2031 → May 2031 and completion Jun 2033 → May 2033.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartActual
Sep 15, 2026was Oct 2026
Primary completionEst.
May 30, 2031was Jun 2031
CompletionEst.
May 27, 2033was Jun 2033
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
208 sites added — first sites in Austria, Brazil, China, France, Germany and 15 more
All 20 countries

Austria, Brazil, China, France, Germany, Hong Kong, Hungary, India, Italy, Japan, Poland, Puerto Rico, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States

. 2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
Show 2 sites
  • Research Site · Ottawa, Canadano status→Not yet recruiting
  • Research Site · Montreal, Canadano status→Recruiting
Show 208 added (42 United States, 27 China, 24 Germany, 21 Japan, 12 Canada, 8 Poland, 8 Spain, 7 Brazil, 7 India, 6 South Korea, 6 Taiwan, 6 Turkey (Türkiye), 6 United Kingdom, 5 France, 5 Hungary, 5 Thailand, 4 Austria, 4 Italy, 2 Hong Kong, 2 Switzerland, 1 Puerto Rico)
  • Research Site · Hot Springs, United States
  • Research Site · Springdale, United States
  • Research Site · Beverly Hills, United States
  • Research Site · Los Alamitos, United States
  • Research Site · Los Angeles, United States
  • Research Site · San Diego, United States
  • Research Site · Margate, United States
  • Research Site · Miami, United States
  • Research Site · Orlando, United States
  • Research Site · Honolulu, United States
  • Research Site · Chicago, United States
  • Research Site · Chicago, United States
  • Research Site · Elk Grove Village, United States
  • Research Site · Hinsdale, United States
  • Research Site · Ames, United States
  • Research Site · Baltimore, United States
  • Research Site · Baltimore, United States
  • Research Site · Towson, United States
  • Research Site · Detroit, United States
  • Research Site · Grand Rapids, United States
  • Research Site · Marshall, United States
  • Research Site · Camden, United States
  • Research Site · Albuquerque, United States
  • Research Site · Shirley, United States
  • Research Site · Canton, United States
  • Research Site · Cincinnati, United States
  • Research Site · Portland, United States
  • Research Site · Portland, United States
  • Research Site · Greenville, United States
  • Research Site · Aberdeen, United States
  • …and 178 more on the registry record
Oct 15, 2026
Start date
Oct 1, 2026→Sep 15, 2026 (actual)
Oct 15, 2026
Primary completion
Jun 17, 2031→May 30, 2031
Oct 15, 2026
Study completion
Jun 14, 2033→May 27, 2033
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    208 sites added — first sites in Austria, Brazil, China, France, Germany and 15 more
    All 20 countries

    Austria, Brazil, China, France, Germany, Hong Kong, Hungary, India, Italy, Japan, Poland, Puerto Rico, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States

    . 2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
    Show 2 sites
    • Research Site · Ottawa, Canadano status→Not yet recruiting
    • Research Site · Montreal, Canadano status→Recruiting
    Show 208 added (42 United States, 27 China, 24 Germany, 21 Japan, 12 Canada, 8 Poland, 8 Spain, 7 Brazil, 7 India, 6 South Korea, 6 Taiwan, 6 Turkey (Türkiye), 6 United Kingdom, 5 France, 5 Hungary, 5 Thailand, 4 Austria, 4 Italy, 2 Hong Kong, 2 Switzerland, 1 Puerto Rico)
    • Research Site · Hot Springs, United States
    • Research Site · Springdale, United States
    • Research Site · Beverly Hills, United States
    • Research Site · Los Alamitos, United States
    • Research Site · Los Angeles, United States
    • Research Site · San Diego, United States
    • Research Site · Margate, United States
    • Research Site · Miami, United States
    • Research Site · Orlando, United States
    • Research Site · Honolulu, United States
    • Research Site · Chicago, United States
    • Research Site · Chicago, United States
    • Research Site · Elk Grove Village, United States
    • Research Site · Hinsdale, United States
    • Research Site · Ames, United States
    • Research Site · Baltimore, United States
    • Research Site · Baltimore, United States
    • Research Site · Towson, United States
    • Research Site · Detroit, United States
    • Research Site · Grand Rapids, United States
    • Research Site · Marshall, United States
    • Research Site · Camden, United States
    • Research Site · Albuquerque, United States
    • Research Site · Shirley, United States
    • Research Site · Canton, United States
    • Research Site · Cincinnati, United States
    • Research Site · Portland, United States
    • Research Site · Portland, United States
    • Research Site · Greenville, United States
    • Research Site · Aberdeen, United States
    • …and 178 more on the registry record
    Start date Oct 1, 2026→Sep 15, 2026 (now actual)
    Primary completion Jun 17, 2031→May 30, 2031
    Study completion Jun 14, 2033→May 27, 2033
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07711002
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Sep 15, 2026
Primary completion
May 30, 2031 (estimated)
Completion
May 27, 2033 (estimated)
Last update
Oct 15, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD5305

Start the discussion